Last reviewed · How we verify
LEGALON
At a glance
| Generic name | LEGALON |
|---|---|
| Also known as | Silymarin |
| Sponsor | Nhat Nhat Pharmaceutical Company |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules (PHASE4)
- Clinical Evaluation of Microneedling Technique With Topical Application of Silymarin on Gingival Hyperpigmentation in Comparison With Diode Laser and Scalpel Methods. (NA)
- Milk Thistle Clinical Trial in Pediatric NAFLD (PHASE2)
- Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo (PHASE2,PHASE3)
- Silymarin vs Hesperidin/Diosmin in Fibromyalgia (NA)
- Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia (NA)
- Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients (NA)
- Study to Evaluate the Effectiveness of Legalon®
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEGALON CI brief — competitive landscape report
- LEGALON updates RSS · CI watch RSS
- Nhat Nhat Pharmaceutical Company portfolio CI